BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that an article describing 100% protection of non-human primates against a highly pathogenic monkeypox challenge after vaccination with its smallpox DNA vaccine has been published in The Journal of Infectious Diseases. Inovio’s DNA vaccine demonstrated strong antibody-based immune responses similar to that of the currently approved live viral vaccine (Dryvax®). The study conducted by Inovio scientists and their collaborators is described in this published paper, entitled, “Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge.”
